Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients.

Conversely, in patients who had undergone prior therapy, the KM curves for PFS between the RS ≥ 0.4 and RS < 0.4 groups showed a statistical trend ( p = 0.068) (Fig. 5 B).

also in 803 other papers

An increasing trend, though not statistically significant, was observed in sPD-L1 levels during the second reassessment after five months in long-term responders (RES) and in those who shifted from response to progression (RES > PD) (median reassessment times: 4–18 and 12–30 months, respectively).

also in 27,205 other papers

Highly significant correlations between sLAG-3 and sCD4 were observed in both RES and NRES groups, suggesting these factors do not play a role in determining immunotherapy response.

also in 36,814 other papers